Mechanism of sorafenib resistance associated with ferroptosis in HCC [PDF]
Frontiers in Pharmacology, 2023 Hepatocellular carcinoma (HCC) is the most familiar primary hepatic malignancy with a poor prognosis. The incidence of HCC and the associated deaths have risen in recent decades.
Lingling Guo +3 more
doaj +6 more sources
Cells, 2022 Sorafenib is a small molecule that blocks tumor proliferation by targeting the activity of multi-kinases for the treatment of advanced hepatocellular carcinoma (HCC). Increasing sorafenib resistance following long-term treatment is frequently encountered.
Yung-Sheng Chang +5 more
doaj +4 more sources
The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma [PDF]
EBioMedicine, 2020 In most cases, sorafenib-resistant HCC cells exhibit significant mesenchymal phenotype and stemness features. In this context, tumor cells might undergo cell fate transition in response to sorafenib or other targeted drugs in the presence or absence of ...
Shunjie Xia +4 more
doaj +5 more sources
Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma [PDF]
Frontiers in Oncology, 2021 Sorafenib a multi-target tyrosine kinase inhibitor, is the first-line drug for treating advanced hepatocellular carcinoma (HCC). Mechanistically, it suppresses tumor angiogenesis, cell proliferation and promotes apoptosis.
Zhi Zeng +15 more
doaj +5 more sources
CD147-positive migrasome macropinocytosis promotes HCC sorafenib resistance via inducing vasculogenic mimicry triggered by PI3K/AKT/TWIST1 signaling [PDF]
Cell Death and DiseaseSorafenib is a widely used targeting drug for hepatocellular carcinoma (HCC) patients; however, sorafenib resistance poses a significant clinical challenge.
Luomeng Qian +8 more
doaj +2 more sources
1D228 Attenuates Sorafenib Resistance in Renal Cell Carcinoma Models by Dual Targeting c-Met and AXL [PDF]
CellsSorafenib is widely used to treat metastatic renal cell carcinoma (RCC); however, the acquired drug resistance limits its efficacy and application in clinical practice.
Hanxu Qian +11 more
doaj +2 more sources
Neoplasia: An International Journal for Oncology Research, 2021 Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), and reducing sorafenib resistance is an important issue to be resolved for the clinical treatment of HCC.
Wenbin Huang +12 more
doaj +3 more sources
Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K/AKT pathway [PDF]
Cell Death and DiseaseSorafenib is an antiangiogenic and antiproliferative chemotherapeutic drug that plays a crucial role in the treatment of patients with advanced hepatocellular carcinoma (HCC). However, resistance to sorafenib greatly limits its therapeutic efficacy. This
Ruimei Ren +8 more
doaj +2 more sources
Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation [PDF]
Frontiers in PharmacologyBackgroundCurcumol, a bioactive sesquiterpenoid extracted from traditional Chinese medicine (TCM), has demonstrated potential in overcoming tumor drug resistance.
Ni Zhang +10 more
doaj +2 more sources
Journal of Experimental & Clinical Cancer Research, 2022 Background Hepatocellular carcinoma (HCC) is one of the most malignant tumors and the fourth leading cause of cancer-related death worldwide. Sorafenib is currently acknowledged as a standard therapy for advanced HCC.
Danyang Li +12 more
doaj +1 more source